The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Protease inhibitors of the sulfonamide type: Anticancer, antiinflammatory, and antiviral agents
Abstract
The sulfonamides constitute an important class of drugs, with several types of pharmacological agents possessing antibacterial, anticarbonic anhydrase, diuretic, hypoglycemic, and antithyroid activity among others. A large number of structurally novel sulfonamide derivatives have ultimately been reported to show substantial protease inhibitory properties. Of particular interest are some metalloprotease inhibitors belonging to this class, which by inhibiting several matrix metalloproteases (MMPs) show interesting antitumor properties. Some of these compounds are currently being evaluated in clinical trials. The large number of sulfonamide MMP inhibitors ultimately reported also lead to the design of effective tumor necrosis factor‐α converting enzyme (TACE) inhibitors, potentially useful in the treatment of inflammatory states of various types. Since both MMPs and TACE contribute synergistically to the pathophysiology of many diseases, such as arthritis, bacterial meningitis, tumor invasion; the dual inhibition of these enzymes emerged as an interesting target for the drug design of anticancer/antiinflammatory drugs, and many such sulfonamide derivatives were recently reported. Human neutrophyl elastase (HNE) inhibitors of the sulfonamide type may also be useful in the treatment of inflammatory conditions, such as emphysema, cystic fibrosis, chronic bronchitis, ischemia reperfusion injury, and acute respiratory distress syndrome. Inhibition of some cysteine proteases, such as several caspase and cathepsin isozymes, may lead to the development of pharmacological agents effective for the management of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, brain damage, and stroke. Another research line that progressed much in the last time regards different sulfonamides with remarkable antiviral activity. Some clinically used HIV protease inhibitors (such as amprenavir) possess sulfonamide moieties in their molecules, which are critical for the potency of these drugs, as shown by means of X‐ray crystallography, whereas a very large number of other derivatives are constantly being synthesized and evaluated in order to obtain compounds with lower toxicity or augmented activity against viruses resistant to the such first generation drugs. Other viral proteases, such as those isolated from several types of herpes viruses may be inhibited by sulfonamide derivatives, leading thus to more effective classes of antiviral drugs. © 2003 Wiley Periodicals, Inc. Med Res Rev, 23, No. 5, 535–558, 2003
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
On the size of the active site in proteases. I. Papain
Schechter, I., & Berger, A. (1967) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(67)80055-x · Cited by 5,204
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760
Supuran, C. T., Scozzafava, A., & Casini, A. (2003) · Medicinal Research Reviews · doi:10.1002/med.10025 · Cited by 1,449
Self-citationDesign and Therapeutic Application of Matrix Metalloproteinase Inhibitors
Whittaker, M., Floyd, C. D., Brown, P., & Gearing, A. J. H. (1999) · Chemical Reviews · doi:10.1021/cr9804543 · Cited by 982
The Role of Interleukin-1 in Disease
Epstein, F. H., Dinarello, C. A., & Wolff, S. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280207 · Cited by 954
Structure and mechanism of interleukin-lβ converting enzyme
Wilson, K. P., Black, J.-A. F., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A., Murcko, M. A., Chambers, S. P., Aldape, R. A., Raybuck, S. A., et al. (1994) · Nature · doi:10.1038/370270a0 · Cited by 847
Strategies in the design of antiviral drugs
De Clercq, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd703 · Cited by 652
Crystal structure of the cysteine protease interleukin-1β-converting enzyme: A (p20/p10)2 homodimer
Walker, N. P. C., Talanian, R. V., Brady, K. D., Dang, L. C., Bump, N. J., Ferenza, C. R., Franklin, S., Ghayur, T., Hackett, M. C., Hammill, L. D., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90303-4 · Cited by 576
Isosterism and molecular modification in drug design
Thornber, C. W. (1979) · Chemical Society Reviews · doi:10.1039/cs9790800563 · Cited by 473
Richman, D. D. (2001) · Nature · doi:10.1038/35073673 · Cited by 419
Matrix metalloproteinases and TIMPs
Woessner, J. F., & Nagase, H. (2000) · Medical Entomology and Zoology · Cited by 380
Tumor necrosis factor-α converting enzyme
Black, R. A. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00097-8 · Cited by 346
MacPherson, L. J., Bayburt, E. K., Capparelli, M. P., Carroll, B. J., Goldstein, R., Justice, M. R., Zhu, L., Hu, S.-I., Melton, R. A., Fryer, L., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960871c · Cited by 326
Sulfonylurea Receptors, Ion Channels, and Fruit Flies
Boyd, A. E. (1988) · Diabetes · doi:10.2337/diab.37.7.847 · Cited by 274
Antiviral drugs: current state of the art
De Clercq, E. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(01)00167-6 · Cited by 263
Applications of carbonic anhydrase inhibitors and activators in therapy
Supuran, C. T., & Scozzafava, A. (2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.2.217 · Cited by 258
Self-citationScozzafava, A., & Supuran, C. T. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000027t · Cited by 225
Self-citationClinical multidrug resistance in cancer: A multifactorial problem
Lehnert, M. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00069-x · Cited by 176
Supuran, C. T., Scozzafava, A., & Clare, B. W. (2002) · Medicinal Research Reviews · doi:10.1002/med.10007 · Cited by 172
Self-citationStructural and biochemical studies of retroviral proteases
Wlodawer, A., & Gustchina, A. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00267-8 · Cited by 166
TACE and other ADAM proteases as targets for drug discovery
Moss, M. L., White, J. M., Lambert, M. H., & Andrews, R. C. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01738-x · Cited by 158
Novel anticancer drug discovery
Buolamwini, J. K. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80073-8 · Cited by 149
Unexpected Binding Mode of a Cyclic Sulfamide HIV-1 Protease Inhibitor
Bäckbro, K., Löwgren, S., Österlund, K., Owera-Atepo, J. B., Unge, T., Hultén, J., Bonham, N. M., Schaal, W., Karlén, A., & Hallberg, A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960588d · Cited by 138
Novel, Nonpeptidic Cyanamides as Potent and Reversible Inhibitors of Human Cathepsins K and L
Falgueyret, J., Oballa, R. M., Okamoto, O., Wesolowski, G. A., Aubin, Y., Rydzewski, R. M., Prasit, P., Riendeau, D., Rodan, S. B., & Percival, M. D. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0003440 · Cited by 129
Blockage of Drug Resistance In Vitro by Disulfiram, a Drug Used to Treat Alcoholism
Loo, T. W. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.898 · Cited by 108
New α-Substituted Succinate-Based Hydroxamic Acids as TNFα Convertase Inhibitors
Barlaam, B. C., Bird, T. G. C., der Brempt, C. L., Campbell, D., Foster, S., & Maciewicz, R. A. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990377j · Cited by 91
Reactivation and role of HHV-8 in Kaposi's sarcoma initiation
Ensoli, B., Stürzl, M., & Monini, P. (2001) · Advances in cancer research · doi:10.1016/s0065-230x(01)81005-8 · Cited by 90
Schröder, J., Henke, A., Wenzel, H., Brandstetter, H., Stammler, H., Stammler, A., Pfeiffer, W. ‐., & Tschesche, H. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010887p · Cited by 88
Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development
Smith, H. J., & Simons, C. (2007) · Cited by 79
Human herpesvirus-8 and Kaposi's sarcoma: Relationship with the multistep concept of tumorigenesis
Stürzl, M., Zietz, C., Monini, P., & Ensoli, B. (2001) · Advances in cancer research · doi:10.1016/s0065-230x(01)81004-6 · Cited by 76
An-Zhi, W., Mayr, I., & Bode, W. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)80118-2 · Cited by 76
Letavic, M. A., Axt, M. Z., Barberia, J. T., Carty, T. J., Danley, D. E., Geoghegan, K. F., Halim, N. S., Hoth, L. R., Kamath, A. V., Laird, E. R., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00183-x · Cited by 75
Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1′ group
Levin, J. I., Chen, J. M., Du, M. T., Nelson, F. C., Killar, L. M., Skala, S., Sung, A., Jin, G., Cowling, R. A., Barone, D., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00136-1 · Cited by 75
Borthwick, A. D., Crame, A. J., Ertl, P. F., Exall, A. M., Haley, T. M., Hart, G. J., Mason, A. M., Pennell, A. M. K., Singh, O. M. P., Weingarten, G. G., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0102203 · Cited by 71
Antiretroviral therapy: state of the HAART
Vella, S., & Palmisano, L. (2000) · Antiviral Research · doi:10.1016/s0166-3542(99)00068-6 · Cited by 69
Gomis‐Rüth, F. X., Meyer, E. F., Kress, L. F., & Politi, V. (1998) · Protein Science · doi:10.1002/pro.5560070207 · Cited by 45
Potential New Therapies for the Treatment of HIV-1 Infection
Condra, J. H., Miller, M. D., Hazuda, D. J., & Emini, E. A. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104110 · Cited by 37
Hanessian, S., BouzBouz, S., Boudon, A., Tucker, G. C., & Peyroulan, D. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00259-0 · Cited by 33
Groutas, W. C., He, S., Kuang, R., et al. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00037-2 · Cited by 33
Tomizawa, N., Ohwada, S., Ohya, T., Takeyoshi, I., Ogawa, T., Kawashima, Y., Adachi, M., & Morishita, Y. (1999) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(99)00030-3 · Cited by 28
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors
Baxter, A. D., Bhogal, R., Bird, J., Keily, J. F., Manallack, D. T., Montana, J. G., Owen, D. A., Pitt, W. R., Watson, R. J., & Wills, R. E. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00259-1 · Cited by 22
Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases
Levin, J. I., Gu, Y., Nelson, F. C., Zask, A., DiJoseph, J. F., Sharr, M. A., Sung, A., Jin, G., Cowling, R. A., Chanda, P. K., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00644-2 · Cited by 20
New trends in antiretroviral therapy for HIV infection
Joly, V., & Yéni, P. (2000) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(00)00112-6 · Cited by 13
Nanteuil, G. D., Portevin, B., & Benoist, A. (2001) · Il Farmaco · doi:10.1016/s0014-827x(01)01027-8 · Cited by 11
Cited by
Sulfonamide drugs: structure, antibacterial property, toxicity, and biophysical interactions
Ovung, A., & Bhattacharyya, J. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00795-9 · Cited by 563
Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas
Cathcart, J., Pulkoski-Gross, A., & Cao, J. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2014.12.002 · Cited by 504
Capasso, C., & Supuran, C. T. (2014) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2013.787422 · Cited by 307
Self-citationStructure, function and applications of carbonic anhydrase isozymes
Imtaiyaz Hassan, M., Shajee, B., Waheed, A., Ahmad, F., & Sly, W. S. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.044 · Cited by 294
Metadata
- Authors
- Supuran, C. T., Casini, A., & Scozzafava, A.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2003-05-09
- Volume
- 23
- Issue
- 5
- Pages
- 535-558
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2168667602
- Cited by
- 431
- References
- 45
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.